{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.96","upperLimit":"8.3","value":"5.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"This measure is the number of months participants remain free from evidence of disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4 mg, days 1, 8, 15.\n\nDexamethasone 40 mg oral weekly.\n\nBendamustine dose levels: 80mg/m2 days 1,2\n\nMLN9708: 4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.\n\nDexamethasone: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.\n\nBendamustine: 80mg/m2 days 1,2","id":"OG000","title":"MLN9708, Bendamustine and Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"For this analysis, all 20 participants who received the fixed dose of 80 mg/m\\^2 Bendamustine and all 8 participants who received Bendamustine (80 mg/m\\^2) in the Dose Escalation phase, were combined.","reportingStatus":"POSTED","timeFrame":"18 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"MONTHS"}